metamizol sodium | Baralgin M tablets, 20 pcs.

release form

Tablets



packaging 20 pcs

Pharmacological action

Baralgin M - NSAIDs, a derivative of pyrazolone, practically does not differ from other NSAIDs in its action mechanism (blocks COX and reduces the formation of Pg from arachidonic acid).

Prevents painful extra- and proprioreceptive impulses from the Gaulle and Burdach beams, raises the threshold of excitability of the thalamic centers of pain sensitivity, increases heat transfer.

A distinctive feature is the slight severity of the anti-inflammatory effect, which causes a weak effect on water-salt metabolism (sodium and water retention) and the gastrointestinal mucosa.

Has analgesic, antipyretic and pronounced antispasmodic (on smooth muscles of the urinary and biliary tract) action.

The action develops after 20-40 minutes and reaches a maximum after 2 hours.

Indications

Severe acute or chronic pain syndrome with injuries and postoperative pain syndrome, with colic, with cancer and other conditions where other therapeutic measures are contraindicated.

Fever resistant to other treatments

Contraindications

- Hypersensitivity to metamizole sodium and other components of the drug, as well as other pyrazolones (phenazone, propiphenazone) or pyrazolidines (phenylbutazone, oxyphenbutazone), including, for example, an indication of the development of agranocyte.

- Violations of bone marrow hematopoiesis (for example, after treatment with cytostatics) or diseases of the hematopoietic system.

- Indications of a history of bronchospasm or other anaphylactic reactions (e.g., urticaria, rhinitis, angioedema) when taking analgesic drugs such as salicylates, paracetamol, diclofenac, ibuprofen, indomethacin, naproxen.

- Congenital insufficiency of glucose-6-phosphate dehydrogenase (risk of hemolysis).

- Children's age (up to 15 years).

- Pregnancy (first and third trimester).

- Lactation.

- Acute intermittent hepatic porphyria (risk of developing porphyria attacks).

If you have one of these diseases or conditions, consult your doctor before taking the drug.

Precautions:

- Hypotension (systolic blood pressure below 100 mmHg), decreased circulating blood volume, hemodynamic instability (myocardial infarction, multiple trauma, onset of shock), beginning heart failure, high fever (increased risk of a sharp decrease in arterial pressure pressure).

- Diseases, in which a significant decrease in blood pressure may be at increased risk (patients with severe coronary heart disease and stenosis of the arteries of the brain).

- Alcoholism.

- Bronchial asthma, especially in combination with concomitant polyposis of rhinosinusitis, chronic urticaria and other types of atopy (allergic diseases, in the development of which a significant role is played by a hereditary predisposition to sensitization: pollinosis, allergic rhinitis, etc.) (increased risk of anaphylactic / anaphylactoid reactions).

- Alcohol intolerance (reaction to even small amounts of certain alcoholic beverages with symptoms such as itching, lacrimation and severe redness of the face) (increased risk of anaphylactic / anaphylactoid reactions).

- Intolerance to dyes (e.g. tartrazine) or preservatives (e.g. benzoates) (increased risk of anaphylactic / anaphylactoid reactions).

- Severe impaired liver and kidney function (low doses are recommended due to the possibility of slowing the elimination of metamizole sodium).

- Pregnancy (second trimester).

If you have one of these diseases or conditions, consult your doctor before taking the drug.

Use during pregnancy and lactation

Contraindicated in the first and third trimesters of pregnancy.

Use in the II trimester - only for strict medical reasons.

Breastfeeding is contraindicated for 48 hours after taking Baralgin M.



composition 1 tablet contains 500 mg metamizole.

Dosage and administration of

Inside, 250-500 mg 2-3 times a day, maximum single dose - 1 g, daily - 3 g.

Single doses for children 2-3 years old - 50-100 mg, 4- 5 years - 100-200 mg, 6-7 years - 200 mg, 8-14 years - 250-300 mg, frequency of administration - 2-3 times a day.

Children are prescribed at a rate of 5-10 mg / kg 2-3 times a day.

Drug Interaction

With cyclosporine

Metamizole sodium may reduce the concentration of cyclosporine in serum, so when used together, the concentration of cyclosporine should be monitored.

With other non-narcotic analgesics

Concomitant use of sodium metamizole with other non-narcotic analgesics can lead to mutual enhancement of toxic effects.

With tricyclic antidepressants, oral contraceptives, allopurinol

Tricyclic antidepressants, oral contraceptives, allopurinol impair the metabolism of sodium metamizole in the liver and increase its toxicity.

With barbiturates, phenylbutazone and other inducers of microsomal liver enzymes

Barbiturates, phenylbutazone and other inducers of microsomal liver enzymes attenuate the action of sodium metamizole.

With sedatives and tranquilizers

Sedatives and tranquilizers enhance the analgesic action of sodium metamizole. Severe hypothermia may develop with the use of metamizole sodium and chlorpromazine.

With drugs that are highly protein bound (oral hypoglycemic agents, indirect anticoagulants, glucocorticosteroids and indomethacin)

Metamizole sodium, ousting oral hypoglycemic agents, indirect anticoagulants, glucocorticosteroid agents and indomethacin from the plasma proteins, enhances their action.

With myelotoxic drugs

Myelotoxic drugs increase the manifestation of hematotoxicity of metamizole sodium.

With methotrexate

Adding metamizole sodium to methotrexate treatment can enhance the haematotoxic effect of methotrexate, especially in the elderly.

Therefore, this combination should be avoided.

With thiamazole and sarcolysin

Thiamazole and sarcolysin increase the risk of leukopenia.

With codeine, H2-histamine receptor blockers and propranolol

Codeine, H2-histamine receptor blockers and propranolol potentiate the effects of metamizole sodium.

X-ray contrast agents, colloidal blood substitutes and penicillin should not be used during sodium metamizole treatment (increased risk of anaphylactic / anaphylactoid reactions).

With acetylsalicylic acid

When used together, metamizole sodium can reduce the effect of acetylsalicylic acid on platelet aggregation. Therefore, this combination should be used with caution in the treatment of patients receiving low doses of acetylsalicylic acid for cardioprotection (thrombosis prevention). With

bupropion Metamizole sodium can reduce the concentration of bupropion in the blood, which should be taken into consideration when metamizole sodium and bupropion are used simultaneously.

overdose

symptoms

Symptoms of overdose may include the following symptoms: nausea, vomiting, abdominal pain, decreased kidney function / acute renal failure with oliguria (eg due to development of interstitial nephrocryptitis), drowsiness, tinnitus, delirium, impaired consciousness, coma, convulsions) and a sharp decrease in blood pressure (sometimes progressing to shock), as well as cardiac arrhythmias (tachycardia), hypothermia, shortness of breath , Acute agranulocytosis, hemorrhagic syndrome, Acute pechenochnaya failure, paralysis d hateln h muscles. Following administration of high doses, excretion of a non-toxic metabolite (rubazonic acid) through the kidneys may cause red staining of urine.

Treatment

If no more than 1-2 hours have passed after taking the drug, then it is possible to induce vomiting, to wash the stomach through the probe to give salt laxatives, activated charcoal. Overdose shows forced diuresis. The major metabolite (4-N-methylaminoantipyrine) can be excreted by hemodialysis, hemofiltration, hemoperfusion or plasma filtration. In the development of convulsive syndrome - intravenous injection of diazepam and high-speed barbiturates.

Storage conditions

In a dark place at a temperature of 8–25 РC

Expiration

4 years.

Active ingredient

Metamizole sodium

Pharmacy terms

Over the counter

Sanofi-Aventis, India